Scarica l'app Stockscreener
1.75
4.78%
0.075
Precedente Chiudi:
$1.675
Aprire:
$1.7
Volume 24 ore:
220.15K
Relative Volume:
0.53
Capitalizzazione di mercato:
$57.25M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.4375
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
+14.71%
1M Prestazione:
+28.10%
6M Prestazione:
-67.56%
1 anno Prestazione:
-76.06%
Intervallo 1D:
$1.65
$1.80
Intervallo di 1 settimana:
$1.53
$2.035
Portata 52W:
$0.87
$9.25
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.755 | 46.97M | 0 | -51.50M | -47.10M | -4.00 |
|
ONC
Beigene Ltd Adr
|
227.80 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.87 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.78 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.08 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News - GuruFocus
Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025 - Stock Titan
Outlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Acquires New Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Russell Investments Group Ltd. Boosts Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
INVESTOR ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World
Outlook Therapeutics Approves Retention Incentive for CFO - MSN
Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com
Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada
FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times
Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa
Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com
Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus
OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha
Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener
FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq
Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire
Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan
Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com
Outlook Therapeutics expands share authorization - Investing.com Australia
Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks
Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK
Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Sun Pharma to Acquire Checkpoint Therapeutics Inc for Up to $355 Million - outlookbusiness.com
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.58%
5.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):